Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PTPRE |
| Gene Name: | PTPRE |
| Protein Full Name: | Receptor-type tyrosine-protein phosphatase epsilon |
| Alias: | EC 3.1.3.48; PTPE; PTP-epsilon; R-PTP-epsilon |
| Mass (Da): | 80642 |
| Number AA: | 700 |
| UniProt ID: | P23469 |
| Locus ID: | 5791 |
| COSMIC ID: | PTPRE |
| Gene location on chromosome: | 10q26 |
| Number of cancer specimens: | 19778 |
| Percent of cancer specimens with mutations: | 0.66 |
| Normal role description: | PTPRE is a protein-tyrosine phosphatase. |
| Commentary on involvement of protein in cancer: | Isoform 1 plays a critical role in signaling transduction pathways and phosphoprotein network topology in red blood cells. May play a role in osteoclast formation and function By similarity. Isoform 2 acts as a negative regulator of insulin receptor (IR) signaling in skeletal muscle. Regulates insulin-induced tyrosine phosphorylation of insulin receptor (IR) and insulin receptor substrate 1 (IRS-1), phosphorylation of protein kinase B and glycogen synthase kinase-3 and insulin induced stimulation of glucose uptake By similarity. Isoform 1 and isoform 2 act as a negative regulator of FceRI-mediated signal transduction leading to cytokine production and degranulation, most likely by acting at the level of SYK to affect downstream events such as phosphorylation of SLP76 and LAT and mobilization of Ca2+ |